enGene Therapeutics (ENGN)
Develops non-viral genetic medicines led by a bladder-cancer therapy candidate.
Something off on this page? Send us feedback.
Develops genetic medicines using the DDX delivery platform, with detalimogene voraplasmid as its lead bladder-cancer program. The clinical-stage company concentrates on localized, non-viral delivery of gene cargos to mucosal tissues and other organs.
Builds genetic medicines around its proprietary Dually Derivatized Oligochitosan (DDX) platform, which is designed for localized, non-viral delivery of multiple gene cargos to mucosal tissues and other organs. Detalimogene voraplasmid, formerly EG-70, is the lead investigational intravesical non-viral gene therapy in study for high-risk non-muscle-invasive bladder cancer.
Operates as a clinical-stage biotechnology company based in Montreal, Quebec, with its Nasdaq listing originating from a 2023 SPAC business combination. The operating business dates to 1999, predating the issuer's short public-company history. Development progress depends on the LEGEND study evaluating detalimogene across high-risk NMIBC cohorts.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | Bank of America Securities | Upgrade | Rating: — | |
| Jun 18, 2026 | Morgan Stanley | Downgrade | Target: — | Target: $3 |
| Jun 16, 2026 | H.C. Wainwright | Target | Target: $25 | Target: $4 |
| May 14, 2026 | UBS | Reiterate | Rating: —Target: $10 | Target: $2 |
| May 8, 2026 | Leerink Partners | Target | Target: $17 | Target: $2 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jul 31, 2026Cash & short-term investments $266.3M · Total debt $33.3M · Total assets $288.3M · Shareholders' equity $230.3M
- Revenue
- $0
- Operating income
- $34.0M
- Net income
- $32.5M
No dividends on record.
| Institutions | 74.26% | 49.76M shares | |
|---|---|---|---|
| 66 holders · as of Jun 30, 2026 | |||
| Insiders | 6.80% | 4.56M shares | |
| 5 holders · as of Jul 22, 2026 | |||
| Strategic holders | 10.97% | 7.35M shares | |
| 2 holders · as of Nov 18, 2025 | |||
| Other | 7.97% | 5.35M shares | |
| remainder | |||
67.02M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FCPM Iii Services B.V.Institution | 14.37% | 9.63M | as of Jun 30, 2026 |
BML Capital Management, LLCInstitution | 9.95% | 6.67M | as of Jun 30, 2026 |
BML Investment Partners, L.P.Institution | 9.95% | 6.67M | filed May 14, 2026 |
Siren, L.L.C.Institution | 9.34% | 6.26M | as of Jun 30, 2026 |
Perceptive Advisors LLCInstitution | 7.20% | 4.82M | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Johnson & Johnson
Approved intravesical gemcitabine system for BCG-unresponsive NMIBC
- ImmunityBio
Approved IL-15 therapy plus BCG for BCG-unresponsive NMIBC
- Merck
Approved anti-PD-1 option for BCG-unresponsive high-risk NMIBC
- CG Oncology
Phase 3 intravesical oncolytic contender in BCG-unresponsive NMIBC
- Protara Therapeutics
Phase 2 intravesical cell therapy in BCG-unresponsive NMIBC
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| enGene Therapeutics | $2.01 | −2.20% | $137.3M | — | — | — | — |
| Johnson & Johnson | $270.83 | +0.61% | $648.72B | 31.2 | 22.8 | 6.6 | +6.6% |
| ImmunityBio | $8.85 | −4.77% | $9.73B | — | — | 58.7 | +93.9% |
| Merck | $149.65 | −0.84% | $372.73B | 120.7 | 17.3 | 5.6 | +5.1% |
| CG Oncology | $76.69 | −1.35% | $6.86B | — | — | 1,101.0 | — |
| Protara Therapeutics | $3.59 | −2.58% | $206.8M | — | — | — | — |
| Median | 76.0 | 20.1 | 32.7 | +6.6% |